Stem cell profit rules urged
By Sacramento Bee,
Sacramento Bee
| 01. 24. 2006
Biotech companies that commercialize taxpayer-funded stem cell research would have to plan to sell the drugs at the "lowest available U.S. commercial price" to low-income Californians, a task force recommended Monday to a citizens group that oversees the state's $3 billion stem cell program.
During a four-hour session at Stanford University, the group also recommended that research grant recipients return 25 percent of income they receive from commercially licensing their stem cell breakthroughs to the state's general fund.
In still another break from federal policy that typically governs such "intellectual property" transactions, members suggested that researchers generally seek nonexclusive licenses for their inventions to provide the maximum potential for fast commercial breakthroughs. Typically, private companies seek exclusive rights to develop a product generated from public research funds.
"Three different companies might pursue that technology three different ways," said Dr. Francisco Prieto, a diabetes specialist at Sutter Medical Group in Elk Grove and task force member who supported the idea.
Monday's recommendations could prove a key turning point in a contentious debate over how Californians and the public treasury will benefit...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...